Clinical Trials Browser

Phase 2/3 × Hematologic Neoplasms × Azacitidine × Clear all

NCT05175508 2022-01-03

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Phase 2/3 Unknown

MyeloidOther hematologic neoplasm

Frailty, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms